 |
BioWorld-International-2004-06-23
No Remicade Valuation Spoils Peptech, Agenix A$500 Merger
No Remicade Valuation Spoils Peptech, Agenix A$500 Merger
SYDNEY, Australia - A friendly A$500 million (US$345 million) merger that promised to create Australia's largest pure biotech company has been called off after hitting a major obstacle over one partner's dispute with a U.S. company. (BioWorld International)